The application from Lykos — a drug business incubated via the Multidisciplinary Affiliation for Psychedelic Studies, or MAPS — arrived on the FDA under a cloud of controversy. Previous trial individuals experienced alleged adverse situations weren't noted — such as thoughts of suicidality once the treatment — and that bias between All thos